Evaluation of the Metabolome in Diverticular Disease
Status:
Unknown status
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect of the probiotic formulation VSL#3 on the metabolome and microbiota of
diverticular disease, comparing it with the effects exerted by supplementation with fibers,
by rifaximin and by mesalazine, and assessing the evolution over time after each specific
treatment